Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial-Reference-Cited by-同舟云学术

Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial

Published:2021-12-23 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chiappella Annalisa¹^ORCID,Diop Fary²,Agostinelli Claudio³,Novo Mattia⁴,Nassi Luca²,Evangelista Andrea⁵,Ciccone Giovannino⁵,Di Rocco Alice⁶,Martelli Maurizio⁶,Melle Federica⁷,Moia Riccardo²^ORCID,Motta Giovanna⁷,Righi Simona³,Santambrogio Elisa⁸,Tucci Alessandra⁹,Balzarotti Monica¹⁰,Ladetto Marco¹¹,Pileri Stefano A.⁷,Gaidano Gianluca²,Vitolo Umberto⁴,

Affiliation:

1. Hematology Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza di Torino TorinoItaly

2. Division of Hematology Department of Translational Medicine Università del Piemonte Orientale NovaraItaly

3. Pathology Unit Università degli Studi di Bologna BolognaItaly

4. Multidisciplinary Oncology Outpatient Clinic Candiolo Cancer Institute FPO‐IRCCS TorinoItaly

5. Unit of Clinical Epidemiology and CPO Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza di Torino TorinoItaly

6. Department of Traslational and Precision Medicine Università La Sapienza RomaItaly

7. Haematopathology Division, IRCCS Istituto Europeo di Oncologia IEO MilanoItaly

8. Hematology Unit Santa Croce e Carle Hospital CuneoItaly

9. Hematology ASST Spedali Civili di Brescia BresciaItaly

10. Unit of Hematology Humanitas Clinical and Research Center RozzanoItaly

11. Hematology Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo Alessandria Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17971

Reference34 articles.

1. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

2. Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

3. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

4. Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma

5. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma;Journal of Blood Medicine;2024-09

2. Minimal residual disease detection in lymphoma: methods, procedures and clinical significance;Frontiers in Immunology;2024-08-12

3. Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome;Cancers;2024-06-07

4. Exome and targeted sequencing in clinical oncology- Diffuse large B-cell lymphoma as a model;Comprehensive Precision Medicine;2024

5. High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma;Blood Advances;2023-12-04